Zacks Investment Research·Jun 19, 2026
10x Genomics, Cleveland Clinic Team Up on Bladder Cancer DiagnosticsTXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xenium and potentially Atera.
10x Genomics, Inc.(TXG)Earnings, Financials & Key Ratios
TXG•NASDAQ
$37.83
Price updated Jul 7, 2026
About10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Show more
- Revenue$643M+5.2%
- EBITDA-$111M+26.5%
- Net Income-$44M+76.2%
- EPS (Diluted)-0.35+77.0%
- Gross Margin69.05%+1.8%
- EBITDA Margin-17.25%+30.2%
- Operating Margin-17.25%+45.8%
- Net Margin-6.77%+77.3%
- ROE-5.78%+77.0%
TXG Price & Volume
10x Genomics, Inc. (TXG) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Obscure Revenue Growth Potential
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Adequate
Cash Flow:Mixed
Primary Risk:Persistent Operating Losses
Key Thesis Takeaways
- 10x Genomics faces a challenging transition as it struggles to achieve consistent profitability, with operating margins remaining negative at -11.3% in 2026Q1.
- While the company maintains a robust gross margin of 70.4%, the reliance on high R&D and SG&A spending continues to erode the bottom line, resulting in a $1.5 billion accumulated deficit in retained earnings.
- Investors should monitor the company's ability to scale the Xenium platform effectively, as current revenue growth has decelerated to -2.6% in the most recent quarter.
Verdict Logic
the company's inability to generate consistent operating income, evidenced by a -11.3% operating margin in 2026Q1, suggests that the current valuation of 7.26x P/S is not supported by sustainable cash generation.
TXG Growth Metrics
10x Genomics, Inc. (TXG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years16.55%
3 Years7.57%
TTM2.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM85.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM86.92%
Return on Capital
10 Years-33.41%
5 Years-18.44%
3 Years-22.48%
Last Year-13.13%
TXG Recent Earnings
10x Genomics, Inc. (TXG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.10+65.5%
$0.29
Rev
$151M+3.0%
$146M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.13+31.6%
$0.19
Rev
$166M+4.0%
$160M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.22-214.3%
$0.07
Rev
$149M+4.6%
$142M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.28+180.0%
$0.35
Rev
$173M+23.9%
$140M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.10vs $0.29+65.5% | $151Mvs $146M+3.0% |
| Q1 2026 | Feb 12, 2026 | $0.13vs $0.19+31.6% | $166Mvs $160M+4.0% |
| Q4 2025 | Nov 6, 2025 | $0.22vs $0.07-214.3% | $149Mvs $142M+4.6% |
| Q3 2025 | Aug 7, 2025 | $0.28vs $0.35+180.0% | $173Mvs $140M+23.9% |
Based on last 12 quarters of dataView full earnings history →
Latest TXG News
Recent stock market news and headlines for 10x Genomics, Inc. (TXG)
Newsfile Corp·Jun 17, 2026
Torex Gold Announces Results of Its 2026 Meeting of ShareholdersMeeting marks formal transition of Andrew Snowden into role of President and CEO Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (OTCQX: TORXF) announces the results of its 2026 annual and special meeting of shareholders (the "Meeting") held virtually today. The Meeting marked the retirement of Jody Kuzenko and the formal appointment of Andrew Snowden as President and CEO of the Company.
Seeking Alpha·Jun 17, 2026
Torex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks TranscriptTorex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks Transcript
PRNewsWire·Jun 17, 2026
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder CancerCollaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.
Peers Comparison
Key metrics vs top competitors for 10x Genomics, Inc. (TXG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $37.83 | $4.8B | -108.09 | 5.25% | -6.77% | -5.78% | — | |
| $1.56 | $484.54M | -0.86 | 3.89% | -80.34% | -488.45% | — | |
| $191.76 | $29.13B | 35.19 | -0.78% | 19.43% | 32.84% | — | |
| $58.25 | $8.87B | -388.33 | 2.08% | -0.34% | -0.5% | — | |
| $21.02 | $596.98M | -10.67 | 13.83% | -23.04% | -6.74% | — | |
| $28.31 | $1.46B | -70.78 | 13.79% | -1.98% | -2.61% | — |
Compare TXG vs Peers
10x Genomics, Inc. (TXG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TXG SEC Filings & Documents
10x Genomics, Inc. (TXG) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 12, 2026·SEC
Material company update
Jan 12, 2026·SEC
10-K Annual Reports
410-Q Quarterly Reports
6Get notified when TXG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TXG Frequently Asked Questions
10x Genomics, Inc. (TXG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is 10x Genomics, Inc.'s revenue?
10x Genomics, Inc. (TXG) reported $638.8M in revenue for fiscal year 2025. This represents a 799% increase from $71.1M in 2017.
How fast is 10x Genomics, Inc. growing?
10x Genomics, Inc. (TXG) grew revenue by 5.2% over the past year. This is steady growth.
Is TXG profitable?
10x Genomics, Inc. (TXG) reported a net loss of $22.7M for fiscal year 2025.
Dividend & Returns
What is TXG's return on equity?
10x Genomics, Inc. (TXG) has a return on equity (ROE) of -5.8%. Negative ROE indicates the company is unprofitable.
What is 10x Genomics, Inc.'s free cash flow?
10x Genomics, Inc. (TXG) generated $122.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.